EZH2: not EZHY (easy) to deal.

Area of Science:

• Epigenetics
• Molecular Biology
• Oncology

Background:

• Epigenetic modifications are crucial for tumor progression.
• Polycomb group (PcG) proteins, particularly within Polycomb repressive complexes (PRC1 and PRC2), regulate gene silencing.
• Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of PRC2, silences tumor suppressor genes via histone H3 trimethylation at lysine 27.

Purpose of the Study:

• To provide a comprehensive overview of the oncogenic role of EZH2 in tumorigenesis.
• To highlight the context-dependent roles of EZH2 as a transcriptional activator or repressor.
• To discuss the causes, consequences, and therapeutic targeting of EZH2 overexpression in various cancers.

Main Methods:

• Literature review of epigenetic mechanisms in cancer.
• Analysis of EZH2's role in gene silencing and transcriptional regulation.
• Examination of clinical evidence linking EZH2 to cancer progression and patient outcomes.

Main Results:

• EZH2 overexpression is strongly associated with cancer progression and poor prognosis in hematologic and epithelial cancers.
• EZH2's regulatory circuits and molecular cues differ across cancer types.
• EZH2's function can be either oncogenic or tumor-suppressive depending on the cellular context.

Conclusions:

• EZH2 is a key epigenetic regulator in cancer development.
• Understanding EZH2's complex regulatory network is vital for designing effective anticancer therapies.
• Targeting EZH2 presents a promising therapeutic avenue, with ongoing research focused on selective inhibition.